BMS’s OPDIVO + Chemo approved in the EU for Neoadjuvant NSCLC (PD-L1 ≥1%)

RenovoRx’s RenovoGem demonstrated positive interim Phase 3 data in Advanced Pancreatic Cancer

Genprex’s REQORSA in combination with Tecentriq received US FDA’s FTD for ES-SCLC

TME Pharma announced positive data from the GLORIA expansion arm in Glioblastoma

CStone and Blueprint’s GAVRETO approved for 1L RET+ NSCLC in China